These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 19395280)

  • 1. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion.
    Thethi TK; Rao A; Kawji H; Mallik T; Yau CL; Christians U; Fonseca V
    J Diabetes Complications; 2010; 24(2):73-8. PubMed ID: 19395280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.
    Raskin P; Holcombe JH; Tamborlane WV; Malone JI; Strowig S; Ahern JA; Lavent F
    J Diabetes Complications; 2001; 15(6):295-300. PubMed ID: 11711322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
    Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
    Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.
    Bode BW; Garg SK; Norwood P; Morales C; Hardy T; Liu R; Ignaut D
    Diabetes Technol Ther; 2021 Jan; 23(1):41-50. PubMed ID: 32640842
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison between preprandial vs. postprandial insulin aspart in patients with type 1 diabetes on insulin pump and real-time continuous glucose monitoring.
    Thuillier P; Sonnet E; Alavi Z; Roudaut N; Nowak E; Dion A; Kerlan V
    Diabetes Metab Res Rev; 2018 Sep; 34(6):e3019. PubMed ID: 29749032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
    Heise T; Meiffren G; Alluis B; Seroussi C; Ranson A; Arrubla J; Correia J; Gaudier M; Soula O; Soula R; DeVries JH; Klein O; Bode B
    Diabetes Obes Metab; 2019 Apr; 21(4):1066-1070. PubMed ID: 30565407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.
    Pozzilli P; Battelino T; Danne T; Hovorka R; Jarosz-Chobot P; Renard E
    Diabetes Metab Res Rev; 2016 Jan; 32(1):21-39. PubMed ID: 25865292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia.
    Beisswenger PJ; Howell SK; O'Dell RM; Wood ME; Touchette AD; Szwergold BS
    Diabetes Care; 2001 Apr; 24(4):726-32. PubMed ID: 11315838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy assessment of online glucose monitoring by a subcutaneous enzymatic glucose sensor during exercise in patients with type 1 diabetes treated by continuous subcutaneous insulin infusion.
    Radermecker RP; Fayolle C; Brun JF; Bringer J; Renard E
    Diabetes Metab; 2013 May; 39(3):258-62. PubMed ID: 23522730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
    Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
    Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study.
    Fresa R; Visalli N; Di Blasi V; Cavallaro V; Ansaldi E; Trifoglio O; Abbruzzese S; Bongiovanni M; Agrusta M; Napoli A
    Diabetes Technol Ther; 2013 Apr; 15(4):328-34. PubMed ID: 23537417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII).
    Shashaj B; Busetto E; Sulli N
    Diabet Med; 2008 Sep; 25(9):1036-42. PubMed ID: 18937673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.
    Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E;
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.